Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatology].

D Mondada1, I Pache, K Leopold

  • 1Service de Gastro-entérologie et d'Hépatologie CHUV, 1011 Lausanne. David.Mondada@chuv.ch

Revue Medicale Suisse
|February 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline characteristics of a diagnostically defined early psychosis cohort entering supported employment and education: findings from the SEEearly trial.

European archives of psychiatry and clinical neuroscience·2026
Same author

Correction: Enhancing educational and vocational recovery in adolescents and young adults with early psychosis through Supported Employment and Education (SEEearly): study protocol for a multicenter randomized controlled trial.

Trials·2023
Same author

Enhancing educational and vocational recovery in adolescents and young adults with early psychosis through Supported Employment and Education (SEEearly): study protocol for a multicenter randomized controlled trial.

Trials·2023
Same author

Management of well appearing infants born to afebrile mothers with inadequate GBS prophylaxis: A retrospective comparison of the three approaches recommended by the COFN.

Journal of neonatal-perinatal medicine·2021
Same author

[Treatment of mentally ill parents-Strengthen awareness for children].

Der Nervenarzt·2021
Same author

The eastern extent of seasonal iron limitation in the high latitude North Atlantic Ocean.

Scientific reports·2019
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Pegylated interferon-alpha (PEG-IFN-alpha), lamivudine, and adefovir improve chronic hepatitis B treatment. New therapies like mycophenolate mofetil and ursodeoxycholic acid (UDCA) offer options for autoimmune hepatitis and primary biliary cirrhosis, respectively.

Area of Science:

  • Hepatology and Gastroenterology
  • Pharmacology and Therapeutics

Context:

  • Chronic hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, and nonalcoholic fatty liver disease represent significant clinical challenges.
  • Current treatments like PEG-IFN-alpha, lamivudine, and adefovir have advanced hepatitis B management.
  • Existing therapies for autoimmune hepatitis and primary biliary cirrhosis have limitations, necessitating alternative approaches.

Purpose:

  • To review current and emerging therapeutic strategies for various chronic liver diseases.
  • To highlight the role of novel agents and combination therapies in improving patient outcomes.
  • To identify areas requiring further clinical investigation for liver disease treatment.

Summary:

  • Pegylated interferon-alpha (PEG-IFN-alpha), lamivudine, and adefovir have improved chronic hepatitis B treatment.

Related Experiment Videos

  • Mycophenolate mofetil is a potential alternative for autoimmune hepatitis non-responders or intolerant patients.
  • Ursodeoxycholic acid (UDCA) is the primary treatment for early-stage primary biliary cirrhosis, improving survival.
  • Thiazolidinediones show promise for nonalcoholic fatty liver disease, pending further research.

    • Impact:

    • Advances in antiviral and immunomodulatory therapies offer improved prognoses for patients with chronic liver conditions.
    • The development of new nucleos(t)ide analogues facilitates more effective combination therapies for viral hepatitis.
    • Early intervention with UDCA in primary biliary cirrhosis is crucial for long-term patient survival.
    • Further research into agents like thiazolidinediones may lead to novel treatments for nonalcoholic fatty liver disease.